Argenx SE Files October 2025 6-K Report
Ticker: ARGX · Form: 6-K · Filed: Oct 3, 2025 · CIK: 1697862
Sentiment: neutral
Topics: sec-filing, 6-k, reporting
TL;DR
Argenx SE filed its October 6-K, standard reporting for foreign issuers.
AI Summary
Argenx SE filed a Form 6-K on October 3, 2025, reporting for the month of October 2025. The filing is from a foreign private issuer and is submitted under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. Argenx SE is incorporated in Belgium and its principal executive offices are located in Amsterdam, the Netherlands.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Argenx SE's ongoing compliance and reporting obligations as a foreign private issuer.
Risk Assessment
Risk Level: low — This filing is a routine report and does not contain new material financial information or strategic changes.
Key Players & Entities
- ARGENX SE (company) — Registrant
- 001-38097 (company) — SEC File Number
- 20251003 (date) — Filing Date
FAQ
What type of company is Argenx SE?
Argenx SE is a company in the Biological Products sector, specifically excluding diagnostic substances, with SIC code 2836.
Where are Argenx SE's principal executive offices located?
Argenx SE's principal executive offices are located at Laarderhoogtweg 25, 1101 EB Amsterdam, the Netherlands.
What is the filing date of this Form 6-K?
This Form 6-K was filed on October 3, 2025.
What is the SEC file number for Argenx SE?
The SEC file number for Argenx SE is 001-38097.
Under which rules is this Form 6-K being submitted?
This Form 6-K is being submitted pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Filing Stats: 284 words · 1 min read · ~1 pages · Grade level 14.3 · Accepted 2025-10-03 16:32:24
Filing Documents
- tm2528000d1_6k.htm (6-K) — 11KB
- tm2528000d1_ex99-1.htm (EX-99.1) — 6KB
- 0001104659-25-096689.txt ( ) — 18KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ARGENX SE Date: October 3, 2025 By: /s/ Hemamalini (Malini) Moorthy Name: Hemamalini (Malini) Moorthy Title: General Counsel